A pharmaceutical partner was developing a new treatment for women undergoing in vitro fertilization. Initially, the company had not included a companion diagnostic (CDx) in its clinical strategy, but as the clinical program progressed, it became clear that such a test would be necessary to seek regulatory approval.

A multinational in vitro diagnostic company (IVD) had developed a multi-analyte cerebral spinal fluid diagnostic panel with utility in identifying patients with early indications of both mild cognitive impairment and full-blown Alzheimer's disease.

Development of new therapies to treat rheumatoid arthritis (RA) shows no sign of waning. It is essential that studies are well designed, meticulously planned, include ongoing data surveillance and have a well-orchestrated patient recruitment strategy.

Despite the widespread availability of highly effective vaccines, chronic hepatitis B infection remains a major global health issue, and there are >350 million people chronically infected with the virus.

ASN 2017 -- Retrospective, real-world data study conducted using end-stage renal disease EMR data from Fresenius Kidney Care centers in the United States.

Oncology trials are undeniably complex. Discover how you can successfully mitigate risks and maximize trial success by creating a comprehensive strategy that plans for the differences in immunotherapy development and proactively monitors execution.

Running biosimilar studies in the U.K. has been a challenge for many pharmaceutical companies who have often struggled to attract clinicians interested in supporting their biosimilar studies.

Conducting a study of an orphan drug to treat pediatric patients with Niemann-Pick disease

Default